CPP (Cancer Prevention Pharmaceuticals) Additional Paid-In Capital : $3.11 Mil(As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Additional Paid-In Capital?

Cancer Prevention Pharmaceuticals's quarterly additional paid-in capital increased from Sep. 2015 ($1.25 Mil) to Dec. 2015 ($1.46 Mil) and increased from Dec. 2015 ($1.46 Mil) to Mar. 2016 ($3.11 Mil).

Cancer Prevention Pharmaceuticals's annual additional paid-in capital increased from Dec. 2013 ($0.86 Mil) to Dec. 2014 ($1.01 Mil) and increased from Dec. 2014 ($1.01 Mil) to Dec. 2015 ($1.46 Mil).

Cancer Prevention Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Additional Paid-In Capital Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Additional Paid-In Capital

0.86

1.01

1.46

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Additional Paid-In Capital	Get a 7-Day Free Trial			1.01	-	1.25	1.46	3.11

Cancer Prevention Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cancer Prevention Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.